Medical Innovation Exchange

AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal

https://www.fiercebiotech.com/biotech/astrazeneca-doubles-down-hot-cancer-target-paying-63m-adc-months-after-bispecific-deal

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!